Bristol Myers Squibb 10-Q 2026-09-30
BMY · CIK 14272 · Form 10-Q · Period ended September 30, 2026 · Filed October 29, 2026
Revenue rose 6.9% to $13.1 billion. Net income was $2.16 billion.
8 sections, 232K characters. Original on sec.gov · ·
| Measure | Quarter ended Sep 30, 2026 | Quarter ended Sep 30, 2025 | Change |
|---|---|---|---|
| Revenue | $13.1B | $12.2B | +6.9% |
| Net income | $2.16B | $2.20B | -1.8% |
| Diluted EPS | $1.05 | $1.08 | -2.8% |
| Cash and equivalents | $9.57B | n/a | n/a |
From the XBRL facts tagged to this filing; both columns are as reported in this filing.
Cover and table of contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2026
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______ to _______
Commission File Number 001-01136
BRISTOL-MYERS SQUIBB COMPANY
(Exact name of registrant as specified in its charter)
| Delaware | 22-0790350 | |||||||
| (State or other jurisdiction of incorporation or organization) | **(**I.R.S. Employer Identification No.) |
Route 206 & Province Line Road, Princeton, New Jersey 08543
(Address of principal executive offices) (Zip Code)
(609) 252-4621
(Registrant’s telephone number, including area code)
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
| Common Stock, $0.10 Par Value | BMY | New York Stock Exchange | ||||||
| Celgene Contingent Value Rights | CELG RT | New York Stock Exchange | ||||||
| 2.973% Notes due 2030 | BMY/30 | New York Stock Exchange | ||||||
| 3.363% Notes due 2033 | BMY/33 | New York Stock Exchange | ||||||
| 1.750% Notes due 2035 | BMY35 | New York Stock Exchange | ||||||
| 3.857% Notes due 2038 | BMY/38 | New York Stock Exchange | ||||||
| 4.289% Notes due 2045 | BMY/45 | New York Stock Exchange | ||||||
| 4.581% Notes due 2055 | BMY/55 | New York Stock Exchange |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to the filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ☒ | Accelerated filer ☐ | Non-accelerated filer ☐ | Smaller reporting company ☐ | Emerging growth company ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
At October 21, 2026, there were 2,044,085,831 shares outstanding of the Registrant’s $0.10 par value common stock.
BRISTOL-MYERS SQUIBB COMPANY
INDEX TO FORM 10-Q
September 30, 2026
Item 1A. [Risk Factors](ib020f3263f224c05800c3dc29271e849208) [45](ib020f3263f224c05800c3dc29271e849208)
| Risk Factors | | | 45 | | | | | | | | | | Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | | | 45 | | | | | | | | | | Item 5. | Other Information | | | 45 | | | | | | | | | | Item 6. | Exhibits | | | 46 | | | | | | | | | | | Summary of Abbreviated Terms | | | 47 | | | | Signatures | | | 48 | | |
- Indicates brand names of products which are trademarks not owned by BMS. Specific trademark ownership information is included in the Exhibit Index at the end of this Quarterly Report on Form 10-Q.
PART I—FINANCIAL INFORMATION
Item 1. FINANCIAL STATEMENTS
BRISTOL-MYERS SQUIBB COMPANY
CONSOLIDATED STATEMENTS OF EARNINGS
Dollars in millions, except per share data
(UNAUDITED)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Net product sales | $ | 12,606 | $ | 11,850 | $ | 36,362 | $ | 34,645 | |||||||||||||||
| Alliance and other revenues | 463 | 372 | 1,169 | 1,047 | |||||||||||||||||||
| Total Revenues | 13,069 | 12,222 | 37,532 | 35,692 | |||||||||||||||||||
| Cost of products sold(a) | 4,146 | 3,435 | 11,292 | 9,839 | |||||||||||||||||||
| Selling, general and administrative | 1,699 | 1,789 | 5,142 | 5,086 | |||||||||||||||||||
| Research and development | 2,365 | 2,528 | 7,973 | 7,365 | |||||||||||||||||||
| Acquired IPRD | 1,558 | 633 | 1,651 | 2,328 | |||||||||||||||||||
| Amortization of acquired intangible assets | 458 | 831 | 1,332 | 2,491 | |||||||||||||||||||
| Other (income)/expense, net | 307 | (108) | 279 | 725 | |||||||||||||||||||
| Total Expenses | 10,533 | 9,108 | 27,670 | 27,834 | |||||||||||||||||||
| Earnings/(Loss) before income taxes | 2,536 | 3,114 | 9,862 | 7,858 | |||||||||||||||||||
| Income tax provision | 374 | 919 | 1,705 | 1,888 | |||||||||||||||||||
| Net earnings/(loss) | 2,162 | 2,195 | 8,156 | 5,970 | |||||||||||||||||||
| Noncontrolling interest | — | (6) | — | 3 | |||||||||||||||||||
| Net earnings/(loss) attributable to BMS | $ | 2,162 | $ | 2,201 | $ | 8,156 | $ | 5,967 | |||||||||||||||
| Earnings/(Loss) per common share: | |||||||||||||||||||||||
| Basic | $ | 1.06 | $ | 1.08 | $ | 4.00 | $ | 2.93 | |||||||||||||||
| Diluted | 1.05 | 1.08 | 3.98 | 2.93 |
(a) Excludes amortization of acquired intangible assets.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/(LOSS)
Dollars in millions
(UNAUDITED)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Net earnings/(loss) | $ | 2,162 | $ | 2,195 | $ | 8,156 | $ | 5,970 | |||||||||||||||
| Other comprehensive income/(loss), net of taxes and reclassifications to earnings: | |||||||||||||||||||||||
| Derivatives qualifying as cash flow hedges | (9) | 48 | 83 | (395) | |||||||||||||||||||
| Pension and postretirement benefits | — | 19 | 8 | 22 | |||||||||||||||||||
| Marketable debt securities | (4) | — | (9) | 2 | |||||||||||||||||||
| Foreign currency translation | 23 | (26) | 160 | 96 | |||||||||||||||||||
| Total other comprehensive income/(loss) | 9 | 41 | 243 | (275) | |||||||||||||||||||
| Comprehensive income/(loss) | 2,171 | 2,236 | 8,399 | 5,695 | |||||||||||||||||||
| Comprehensive income/(loss) attributable to noncontrolling interest | — | (6) | — | 3 | |||||||||||||||||||
| Comprehensive income/(loss) attributable to BMS | $ | 2,171 | $ | 2,242 | $ | 8,399 | $ | 5,692 |
The accompanying notes are an integral part of these consolidated financial statements.
BRISTOL-MYERS SQUIBB COMPANY
CONSOLIDATED BALANCE SHEETS
Dollars in millions
(UNAUDITED)
| ASSETS | September 30, 2026 | December 31, 2025 | |||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 9,574 | $ | 10,209 | |||||||
| Marketable debt securities | 3,007 | 464 | |||||||||
| Receivables | 10,639 | 11,414 | |||||||||
| Inventories | 2,704 | 2,690 | |||||||||
| Other current assets | 3,844 | 4,613 | |||||||||
| Total Current assets | 29,767 | 29,390 | |||||||||
| Property, plant and equipment | 7,971 | 7,543 | |||||||||
| Goodwill | 21,735 | 21,754 | |||||||||
| Other intangible assets | 16,936 | 19,103 | |||||||||
| Deferred income taxes | 5,884 | 5,378 | |||||||||
| Marketable debt securities | 378 | 396 | |||||||||
| Other non-current assets | 6,099 | 6,474 | |||||||||
| Total Assets | $ | 88,772 | $ | 90,038 | |||||||
| LIABILITIES | |||||||||||
| Current liabilities: | |||||||||||
| Short-term debt obligations | $ | 1,028 | $ | 2,261 | |||||||
| Accounts payable | 4,628 | 3,575 | |||||||||
| Other current liabilities | 13,098 | 17,581 | |||||||||
| Total Current liabilities | 18,753 | 23,417 | |||||||||
| Deferred income taxes | 228 | 222 | |||||||||
| Long-term debt | 41,849 | 42,850 | |||||||||
| Other non-current liabilities | 4,538 | 5,043 | |||||||||
| Total Liabilities | 65,368 | 71,533 | |||||||||
| Commitments and Contingencies (see Note 18) | |||||||||||
| EQUITY | |||||||||||
| BMS Shareholders’ equity: | |||||||||||
| Preferred stock | — | — | |||||||||
| Common stock | 292 | 292 | |||||||||
| Capital in excess of par value of stock | 46,674 | 46,387 | |||||||||
| Accumulated other comprehensive loss | (1,281) | (1,524) | |||||||||
| Retained earnings | 21,190 | 16,896 | |||||||||
| Less cost of treasury stock | (43,471) | (43,579) | |||||||||
| Total BMS Shareholders’ equity | 23,404 | 18,473 | |||||||||
| Noncontrolling interest | — | 33 | |||||||||
| Total Equity | 23,404 | 18,506 | |||||||||
| Total Liabilities and Equity | $ | 88,772 | $ | 90,038 |
The accompanying notes are an integral part of these consolidated f
Showing the first 8K of 125K characters. Open the full section
Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Management’s discussion and analysis of financial condition and results of operations is provided as a supplement to and should be read in conjunction with the consolidated financial statements and related footnotes included elsewhere in this Quarterly Report on Form 10-Q to enhance the understanding of our results of operations, financial condition and cash flows. Certain amounts in this Quarterly Report on Form 10-Q may not sum due to rounding. Percentages have been calculated using unrounded amounts.
EXECUTIVE SUMMARY
Our principal strategy is to combine the resources, scale and capability of a large pharmaceutical company with the speed, agility and focus on innovation typically found in the biotech industry. Our focus as a biopharmaceutical company is on discovering, developing and delivering transformational medicines for patients facing serious diseases in areas where we believe that we have an opportunity to make a meaningful difference: oncology, hematology, immunology, cardiovascular, neuroscience and other areas where we can also create long-term value. Our priorities are to focus on transformational medicines where we have a competitive advantage, drive operational excellence and strategically allocate capital for long-term growth and shareholder returns. Our R&D strategy is designed to invest in the most promising science and to consistently execute in a way that translates that science into new medicines with the highest probability of success. To execute this strategy, we focus on three key priorities: science, execution, and value. Additionally, we are driving commercial execution in our key first-in-class and/or best-in-class marketed products, where we continue to expand and see potential for further expansion into the future. For further information on our strategy, see "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations—Executive Summary—Strategy" in our 2025 Form 10-K. Refer to the Summary of Abbreviated Terms at the end of this Quarterly Report on Form 10-Q for terms used throughout the document.
In 2026, we have achieved multiple regulatory approvals across our portfolio, including: (i) approval of our first CELMoD, Zenbexus (iberdomide), in combination with daratumumab and hyaluronidase-fihj and dexamethasone for the treatment of adult patients with MM who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent in the U.S.; (ii) approval of Camzyos for pediatric patients with symptomatic oHCM in the U.S.; (iii) approval of Sotyktu for the treatment of adults with active PsA in the U.S. and EU; and (iv) approval of Opdivo for cHL in the U.S. and EU. We have also made meaningful progress advancing our pipeline, highlighted by: (i) topline Phase III results from the ALOFT-IPF study of admilparant in adults with IPF, which met its primary endpoint at the 60 mg dose; (ii) positive topline interim Phase III results from the ACTION-1 study of RYZ101 in patients with SSTR+ GEP-NETs who have progressed following Lu177-based therapy; (iii) FDA acceptance of our NDA for mezigdomide in RRMM with a PDUFA date of May 13, 2027; (iv) positive interim Phase II results from the ROSETTA Lung-02 study of pumitamig in patients with previously untreated advanced NSCLC; (v) positive topline Phase II results from the registrational QUINTESSENTIAL study of arlo-cel in adult patients with quadruple-class exposed RRMM; and (vi) positive interim results from two Phase III studies conducted in China for iza-bren in heavily pretreated, unresectable locally advanced or metastatic TNBC and recurrent or metastatic ESCC.
We continue to view business development as an important component of our strategy, focusing on opportunities where we can add strategic value and deliver returns. In May 2026, we entered into global license agreements with Hengrui to develop and commercialize 13 early stage assets in oncology, hematology and immunology. For additional information relating to this arrangement, refer to "Item 1. Financial Statements — Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements". Additionally, in August 2026, we announced plans to build a new, state-of-the-art multi-modal manufacturing campus in Houston, Texas, and a new, radiopharmaceutical manufacturing facility in Whitestown, Indiana, reflecting our continuing efforts to invest in research and development, technology and domestic production within the U.S.
We remain committed to the strategic allocation of resources and investing in areas that maximize value and drive sustainable growth. As previously announced, our ongoing strategic productivity initiative includes acceleration of the delivery of medicines to patients by evolving and streamlining our enterprise operating model in key areas such as R&D, manufacturing, commercial and other functions. As a result of an expansion in 2025, we expect to realize annual cost savings of approximately $2.0 billion by the end of 2027. The exit costs resulting from these actions are included in our updated 2023 Restructuring Plan.
Financial Highlights
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| Dollars in millions, except per share data | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Total Revenues | $ | 13,069 | $ | 12,222 | $ | 37,532 | $ | 35,692 | |||||||||||||||
| Diluted earnings/(loss) per share | |||||||||||||||||||||||
| GAAP | $ | 1.05 | $ | 1.08 | $ | 3.98 | $ | 2.93 | |||||||||||||||
| Non-GAAP | 1.35 | 1.63 | 4.97 | 4.89 |
Revenues increased 7% during the third quarter of 2026 and 5% year-to-date, primarily reflecting higher demand and higher average net selling prices across the Growth Portfolio and for Eliquis, which was partially offset by the impact of generics across the remainder of the Legacy Portfolio*.*
The $0.03 decrease in GAAP EPS for the third quarter of 2026 was primarily due to higher one-time Acquired IPRD charges in 2026 and the expiry of royalty income on diabetes products at the end of 2025, partially offset by lower amortization of acquired intangible assets and higher revenues in 2026. After adjusting for specified items, the $0.28 decrease in non-GAAP EPS was primarily due to the aforementioned higher Acquired IPRD charges and the expiry of royalty income on diabetes products, partially offset by higher revenues.
The $1.05 increase in GAAP EPS year-to-date was primarily due to lower amortization of acquired intangible assets, lower one-time Acquired IPRD charges and higher revenues in 2026, partially offset by the expiry of royalty income on diabetes products at the end of 2025. After adjusting for specified items, the $0.08 increase in non-GAAP EPS was primarily due to the aforementioned lower Acquired IPRD charges and higher revenues, partially offset by the expiry of royalty income on diabetes products.
Our non-GAAP financial measures, including non-GAAP earnings and related EPS information, are adjusted to exclude specified items that represent certain costs, expenses, gains and losses and other items impacting the comparability of financial results. For further information and reconciliations relating to our non-GAAP financial measures refer to "—Non-GAAP Financial Measures."
Economic and Market Factors
Governmental Actions
Ongoing regulatory focus on prescription
Showing the first 8K of 87K characters. Open the full section
Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
For a discussion of our market risk, refer to "Item 7A. Quantitative and Qualitative Disclosures about Market Risk" in our 2025 Form 10-K. There have been no material changes to our market risk during the nine months ended September 30, 2026.
Item 4. CONTROLS AND PROCEDURES
Management carried out an evaluation, under the supervision and with the participation of its chief executive officer and chief financial officer, of the effectiveness of the design and operation of its disclosure controls and procedures, as defined in Exchange Act Rules 13a-15(e) and 15d-15(e), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our principal executive officer and principal financial officer concluded that as of September 30, 2026, such disclosure controls and procedures are effective.
There were no changes in the Company's internal control over financial reporting during the quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.
PART II—OTHER INFORMATION
Item 1. LEGAL PROCEEDINGS
Information pertaining to legal proceedings can be found in "Item 1. Financial Statements—Note 18. Legal Proceedings and Contingencies," to the interim consolidated financial statements, and is incorporated by reference herein.
Item 1A. RISK FACTORS
There have been no material changes from the risk factors disclosed in the Company's 2025 Form 10-K.
Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
The following table summarizes the surrenders of our equity securities during the three months ended September 30, 2026:
| Period | Total Number of Shares Purchased**(a)** | Average Price Paid per Share**(a)** | Total Number of Shares Purchased as Part of Publicly Announced Programs**(b)** | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Programs**(b)** | |||||||||||||||||||
| Dollars in millions, except per share data | |||||||||||||||||||||||
| July 1 to 31, 2026 | 71,019 | $ | 62.24 | — | $ | 5,014 | |||||||||||||||||
| August 1 to 31, 2026 | 7,410 | $ | 62.94 | — | $ | 5,014 | |||||||||||||||||
| September 1 to 30, 2026 | 26,634 | $ | 66.69 | — | $ | 5,014 | |||||||||||||||||
| Three months ended September 30, 2026 | 105,063 | — |
(a)Includes shares of common stock surrendered to the Company to satisfy tax withholding obligations in connection with the vesting of awards under our long-term incentive program.
(b)In May 2010, the Board of Directors authorized the repurchase of up to $3.0 billion of our common stock. From time to time thereafter, the Board approved additional share repurchase authorizations totaling an amount of $25.0 billion, including the most recent authorization of $3.0 billion in December 2023. The remaining share repurchase capacity under the program was $5.0 billion as of September 30, 2026. Our share repurchase program does not obligate us to repurchase any specific number of shares, does not have a specific expiration date and may be suspended or discontinued at any time.
Item 5. OTHER INFORMATION
Rule 10b5-1 Trading Arrangement
During the three months ended September 30, 2026, no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.
Item 6. EXHIBITS
Exhibits (listed by number corresponding to the Exhibit Table of Item 601 in Regulation S-K).
| Exhibit No. | Description | |||||||
| 22. | Subsidiary Issuers of Guaranteed Securities (incorporated by reference to Exhibit 22 of Bristol Myers Squibb Company's Annual Report on Form 10-K filed on February 11, 2026) | |||||||
| 31a. | Section 302 Certification Letter (filed herewith). | |||||||
| 31b. | Section 302 Certification Letter (filed herewith). | |||||||
| 32a. | Section 906 Certification Letter (furnished herewith). | |||||||
| 32b. | Section 906 Certification Letter (furnished herewith). | |||||||
| 101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | |||||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. | |||||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | |||||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. | |||||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. | |||||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | |||||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
- Indicates, in this Quarterly Report on Form 10-Q, brand names of products, which are registered trademarks not solely owned by the Company or its subsidiaries. Keytruda and Winrevair are trademarks of Merck; Plavix is a trademark of Sanofi; and Tecentriq is a trademark of Genentech, Inc. Brand names of products that are in all italicized letters, without an asterisk, are registered trademarks of BMS and/or one of its subsidiaries.
SUMMARY OF ABBREVIATED TERMS
Bristol-Myers Squibb Company and its consolidated subsidiaries may be referred to as Bristol Myers Squibb, BMS, the Company, we, our or us in this Quarterly Report on Form 10-Q, unless the context otherwise indicates. Throughout this Quarterly Report on Form 10-Q we have used terms which are defined below:
| 2025 Form 10-K | Annual Report on Form 10-K for the fiscal year ended December 31, 2025 | MCL | mantle cell lymphoma | ||||||||
| 2seventy bio | 2seventy bio, Inc. | Merck | Merck & Co., Inc., Rahway, NJ, USA | ||||||||
| ANDA | Abbreviated New Drug Application | MF | myelofibrosis | ||||||||
| AOCL | Accumulated other comprehensive loss | Mirati | Mirati Therapeutics, Inc. | ||||||||
| AstraZeneca | AstraZeneca PLC | MM | multiple myeloma | ||||||||
| AVD | doxorubicin, vinblastine and dacarbazine | MZL | marginal zone lymphoma | ||||||||
| BioArctic | BioArctic AB | NDA | New Drug Application | ||||||||
| BioNTech | BioNTech SE | NSCLC | non-small cell lung cancer | ||||||||
| Celgene | Celgene Corporation | NYHA | New York Heart Association | ||||||||
| CELMoD | cereblon E3 ligase modulator | oHCM | Obstructive Hypertrophic Cardiomyopathy | ||||||||
| CERCLA | U.S. Comprehensive Environmental Response, Compensation and Liability Act | Ono | Ono Pharmaceutical Co., Ltd | ||||||||
| cHL | classical Hodgkins Lymphoma | PD-1 | programmed cell death protein 1 | ||||||||
| CRC | colorectal cancer | PD-L1 | programmed death-ligand 1 | ||||||||
| CVR | Contingent value right | PDUFA | Prescription Drug User Fee Act | ||||||||
| Dr. Reddy's Laboratories | Dr. Reddy's Laboratories, Limited and Dr. Reddy's Laboratories, Inc. | Philochem | Philochem AG | ||||||||
| DVd | daratumumab, bortezomib and dexamethasone | Pfizer | Pfizer, Inc. | ||||||||
| EC | European Commission | PFS | progression-free survival | ||||||||
| EPS | earnings per share | PsA | psoriatic arthritis | ||||||||
| ESCC | esophageal squamous cell carcinoma | Quarterly Report on Form 10-Q | Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 | ||||||||
| ES-SCLC | extensive stage small cell lung cancer | R&D | research and development | ||||||||
| EU | European Union | RDFV | readily determinable fair values | ||||||||
| Evotec | Evotec SE | REMS | risk evaluation and mitigation strategy | ||||||||
| Exchange Act | the Securities Exchange Act of 1934 | Roche | F. Hoffman-La Roche & Co. | ||||||||
| FASB | Financial Accounting Standards Board | RRMM | relapsed or refractory multiple myeloma | ||||||||
| FDA | U.S. Food and Drug Administration | Sanofi | Sanofi S.A. | ||||||||
| GAAP | generally accepted accounting principles | SAR | Special Administrative Region | ||||||||
| GEP-NETs | gastroenteropancreatic neuroendocrine tumors | SEC | U.S. Securities and Exchange Commission | ||||||||
| GTN | gross-to-net | SPC | Supplementary Protection Certificate | ||||||||
| HCM | hypertrophic cardiomyopathy | SSTR+ | somatostatin receptor-positive | ||||||||
| Hengrui | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | SystImmune | SystImmune, Inc. | ||||||||
| HHS | Health and Human Services | TNBC | triple negative breast cancer | ||||||||
| IPF | idiopathic pulmonary fibrosis | UK | United Kingdom | ||||||||
| IPRD | in-process research and development | U.S. | United States | ||||||||
| IRA | Inflation Reduction Act of 2022 | VAT | value added tax | ||||||||
| IRS | Internal Revenue Service | VEGF-A | Vascular endothelial growth factor A | ||||||||
| IT | Information Technology | ||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| BRISTOL-MYERS SQUIBB COMPANY (REGISTRANT) | |||||||||||
| Date: | October 29, 2026 | By: | /s/ Christopher Boerner, Ph.D. | ||||||||
| Christopher Boerner, Ph.D. Chair of the Board and Chief Executive Officer | |||||||||||
| Date: | October 29, 2026 | By: | /s/ David V. Elkins | ||||||||
| David V. Elkins Chief Financial Officer |